Chinese Vape Makers Exploit Regulatory Gaps With Potent Nicotine Analogs
While the Trump administration proposes expanding nicotine definitions in its 2027 budget, Chinese manufacturers are currently flooding the US market with unregulated products containing chemicals that animal studies suggest are more addictive than traditional nicotine.
Chinese vape manufacturers are capitalising on a regulatory loophole in US law by selling products containing nicotine analogs, such as 6-methyl-nicotine, to circumvent federal bans on flavoured nicotine vapes. While major US tobacco companies researched these compounds decades ago, they were never commercialised; however, Chinese firms are now filling vapes with these little-studied chemicals, which mimic nicotine’s effects. Current US regulations narrowly define nicotine, excluding these analogs from Food and Drug Administration (FDA) oversight.
Although the Trump administration has proposed expanding the definition of nicotine to include these analogs in its fiscal year 2027 budget, comprehensive federal regulation remains absent. Consequently, enforcement is largely falling to individual states, with California, Nebraska, Indiana, and Tennessee having already expanded their definitions of tobacco products to explicitly include nicotine-like chemicals. This state-level fragmentation occurs despite the administration’s proposal to treat these substances similarly to tobacco-derived or synthetic nicotine.
The shift towards nicotine analogs follows the 2022 closure of the synthetic nicotine loophole by Congress. Prior to this legislative change, manufacturers had relied on synthetic nicotine to avoid FDA oversight. Now, Chinese producers are utilising compounds that are not currently captured by the narrow legal definition of nicotine. This allows them to market products without submitting them for the scientific review required for legally marketed tobacco products.
Health risks associated with these analogs remain poorly understood in humans, though animal studies indicate that 6-methyl-nicotine may be more potent and addictive than regular nicotine. A 2024 study further revealed that some nicotine analog vapes contain additional unlabeled ingredients, including artificial sweeteners and cooling agents with unknown inhalation risks. Experts note a significant disconnect between product labels and actual contents, raising concerns about consumer safety.
If the proposed regulatory change is enacted, it would close the loophole currently exploited by Chinese vape manufacturers. However, the change would also allow major US tobacco companies to potentially legally develop and sell their own nicotine analog products, provided they comply with FDA requirements. Critics argue this shift aligns with the interests of large domestic tobacco firms losing market share to Chinese startups, rather than solely addressing public health concerns.
